Luc Friboulet

23PUBLICATIONS
163CO-AUTHORS
Molecular targetsPredictive and prognostic markersLiquid biopsiesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Feb 03, 2026
Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.

Francesco Facchinetti, Antoine Hollebecque, Rémy Barbé

|Oct 04, 2024
The genomic and transcriptomic landscape of metastastic urothelial cancer.

Yohann Loriot, Maud Kamal, Laurene Syx

|Sep 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.

Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul

|Sep 03, 2024
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.

Francesco Facchinetti, Yohann Loriot, Floriane Brayé

|Apr 17, 2024
Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN Alterations.

Ursula Grazini, Aleksandra Markovets, Lucy Ireland

|Feb 26, 2024
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients.

Damien Vasseur, Ahmadreza Arbab, Fabiola Giudici

Pageof 4

Frequent Collaborators

10 joint publications

Benjamin Besse

8 joint publications

Antoine Hollebecque

8 joint publications

Yohann Loriot

7 joint publications

Ludovic Lacroix